Insulin aspart (Fiasp) vs THDB0206

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

Insulin aspart (Fiasp)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07652528 (registry estimate)

No aligned efficacy figure on record for this race.

THDB0206

Developed by Adocia and partners

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT05834868 · Phase 3 · completed

The study was randomized and actively controlled with insulin lispro, but it was open-label and used change in HbA1c as its primary, surrogate endpoint rather than a hard clinical outcome. Registry results are not posted; the sponsors (Adocia and Tonghua Dongbao) announced positive topline results versus Humalog in July 2025, so the result rests on a company announcement.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin aspart (Fiasp)THDB0206
HbA1c, change6.6% vs 6.6%vs NovoRapidwk 26 · n 345NCT01819129
2 other results
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • 6.8% vs 7.7% wk 18 · n 116 · Phase 3 · primary NCT01850615
—Not posted · NCT05834868
Body weight, change (kg)1.2 vs 1.1vs NovoRapidwk 16 · n 522NCT03268005—Not posted · NCT05834868
HbA1c below 7%—Not reported—Not posted · NCT05834868
Fasting plasma glucose, change0.6 vs 0.7vs NovoRapidwk 16 · n 533NCT03268005—Not posted · NCT05834868
3-point MACE (% with event)—Not reported—Not posted · NCT05834868

HbA1c, change

Insulin aspart (Fiasp)
6.6% vs 6.6%vs NovoRapidwk 26 · n 345NCT01819129
2 other results
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • 6.8% vs 7.7% wk 18 · n 116 · Phase 3 · primary NCT01850615
THDB0206
—Not posted · NCT05834868

Body weight, change (kg)

Insulin aspart (Fiasp)
1.2 vs 1.1vs NovoRapidwk 16 · n 522NCT03268005
THDB0206
—Not posted · NCT05834868

HbA1c below 7%

Insulin aspart (Fiasp)
—Not reported
THDB0206
—Not posted · NCT05834868

Fasting plasma glucose, change

Insulin aspart (Fiasp)
0.6 vs 0.7vs NovoRapidwk 16 · n 533NCT03268005
THDB0206
—Not posted · NCT05834868

3-point MACE (% with event)

Insulin aspart (Fiasp)
—Not reported
THDB0206
—Not posted · NCT05834868
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

THDB0206: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Insulin aspart (Fiasp): 4 of 4 rows · THDB0206: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin aspart (Fiasp)
Dropout rate
12.8%a
NCT01819129 · Phase 3
show 2 more results
7.8%
NCT01850615 · Phase 3 · combination
2.7%
NCT03268005 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
0.3%a
NCT01819129 · Phase 3
show 2 more results
1.7%
NCT01850615 · Phase 3 · combination
—
NCT03268005 · Phase 3 · registry result, not featured evidence
Serious AEs
4.4%a
NCT01819129 · Phase 3
show 2 more results
5.2%
NCT01850615 · Phase 3 · combination
7%
NCT03268005 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
urinary tract infection 5.9%
nasopharyngitis 5%
upper respiratory tract infection 4.7%
NCT01819129 · Phase 3
show 2 more results
diarrhoea 1.7%
NCT01850615 · Phase 3 · combination
nasopharyngitis 5.9%
NCT03268005 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin aspart (Fiasp)

HbA1c 6.63% (n=345) vs 6.59% (n=344) NovoRapid @ 26wk
absolute change · percentage points
NCT01819129 · Phase 3
show 2 more results
6.78% (n=116) vs 7.7% (n=120) Basal @ 18wk
NCT01850615 · Phase 3 · combination
-0.15% (n=544) vs -0.09% (n=539) NovoRapid @ 16wk
NCT03268005 · Phase 3 · registry result, not featured evidence
PPG Excursion 4.55 vs 4.9 NovoRapid mmol/L @ 26wk
absolute change · mmol/L
NCT01819129 · Phase 3
show 1 more result
-0.43 vs 0.08 NovoRapid mmol/L @ 16wk
NCT03268005 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose 0.56 vs 0.68 NovoRapid mmol/L @ 16wk
absolute change · mmol/L
NCT03268005 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 49.6% (n=546) vs 51.7% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 271 Participants as posted
HbA1c Less Than 7 Without Severe Hypoglycemia 48.5% (n=546) vs 51% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 265 Participants as posted
SMBG Daily Average -0.56 vs -0.5 NovoRapid mmol/L @ 16wk
absolute change · mmol/L
NCT03268005 · Phase 3 · registry result, not featured evidence
SMPG-mean Post Prandial Increment -0.48 vs -0.23 NovoRapid mmol/L @ 16wk
absolute change · mmol/L
All meals
NCT03268005 · Phase 3 · registry result, not featured evidence
Postprandial Glucose Leq 7.8 34.1% (n=546) vs 35.2% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 186 Participants as posted
Postprandial Glucose Leq 7.8 mmol/L Without Severe Hypoglycemia 33.3% (n=546) vs 34.9% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 182 Participants as posted
Weight 1.19 vs 1.12 NovoRapid kg @ 16wk
absolute change · kg
NCT03268005 · Phase 3 · registry result, not featured evidence
BMI 0.43 vs 0.4 NovoRapid kg @ 16wk
absolute change · kg
NCT03268005 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin aspart (Fiasp)'s landscape · THDB0206's landscape